Platinib’s lung cancer cure rate is beyond imagination

Pralsetinib (Pralsetinib) is a cancer drug used to treat advanced non-small cell lung cancer, which is caused by changes in a gene called RET (called RET fusion-positive non-small cell lung cancer) and has not yet been treated with RET inhibitors. Pratinib contains the active substance pralsetinib.

In a major study, platinib was effective in shrinking tumors in patients with previously untreated RET fusion-positive non-small cell lung cancer and those who had previously received platinum-based chemotherapy. Response to treatment is assessed using body scans, with a complete response being considered when the patient has no remaining signs of cancer. Approximately 72% of previously untreated patients had a complete or partial response to platinib treatment. Approximately 59% of patients who received platinib following platinum-based chemotherapy had a complete or partial response to platinib. Cure rate essentially refers to the proportion of patients whose disease completely disappears, while cure for cancer often involves longer follow-up and evaluation, and more data is needed to determine.

The original drug Platinib has been launched in China, but it has not yet passed the relevant policies for inclusion in medical insurance. The price of 120 pills per box may be around 60,000 yuan. The price of the European version of Platinib's original drug sold overseas may be around RMB 40,000 per box of 60 pills, and the U.S. version may be priced around RMB 150,000 per box (the price may fluctuate due to exchange rates), which is expensive. There are also generic Platinib drugs available for sale overseas. The ingredients of the drug are basically the same as those of the original drug at home and abroad. The price of 120 pills per box may be more than RMB 4,000 (the price may fluctuate due to the exchange rate).